Selective Alpha-Particle Mediated Depletion of Tumor Vasculature with Vascular Normalization

• Jaspreet Singh Jaggi ,

  Contributed equally to this work with: Jaspreet Singh Jaggi, Erik Henke

  Affiliation Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Erik Henke ,

  Contributed equally to this work with: Jaspreet Singh Jaggi, Erik Henke

  Affiliation Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Surya V. Seshan,

  Affiliation Department of Pathology, Weill Medical College of Cornell University, New York, New York, United States of America

  ⨯
• Barry J. Kappel,

  Affiliation Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Debjit Chattopadhyay,

  Affiliation Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Chad May,

  Affiliation ImClone Systems Incorporated, New York, New York, United States of America

  ⨯
• Michael R. McDevitt,

  Affiliation Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Daniel Nolan,

  Affiliation Cold Spring Harbor Laboratory, Woodbury, New York, United States of America

  ⨯
• Vivek Mittal,

  Affiliation Cold Spring Harbor Laboratory, Woodbury, New York, United States of America

  ⨯
• Robert Benezra,

  Affiliation Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• David A. Scheinberg

  *To whom correspondence should be addressed. E-mail: d-scheinberg@ski.mskcc.org

  Affiliation Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯